Testing effectiveness (Phase 2)UnknownNCT04354961
What this trial is testing
Almonertinib as First-line Treatment in Patients With EGFR+ Positive Pulmonary Adenosquamous Carcinoma or Combined Adenocarcinoma and Squamous Cell Carcinoma
Who this might be right for
Pulmonary Adenosquamous Carcinoma
Fujian Cancer Hospital 13